Fortress Biotech (NASDAQ: FBIO) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.


This table compares Fortress Biotech and MediWound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortress Biotech -53.95% -54.88% -30.67%
MediWound -752.78% -326.32% -48.65%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Fortress Biotech and MediWound, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortress Biotech 0 0 5 0 3.00
MediWound 0 0 4 0 3.00

Fortress Biotech presently has a consensus target price of $10.60, indicating a potential upside of 136.61%. MediWound has a consensus target price of $10.33, indicating a potential upside of 69.40%. Given Fortress Biotech’s higher possible upside, equities analysts plainly believe Fortress Biotech is more favorable than MediWound.

Risk and Volatility

Fortress Biotech has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.

Institutional and Insider Ownership

12.0% of Fortress Biotech shares are owned by institutional investors. Comparatively, 23.5% of MediWound shares are owned by institutional investors. 31.5% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Fortress Biotech and MediWound’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Fortress Biotech $108.97 million 2.08 -$71.48 million ($1.48) -3.03
MediWound $2.17 million 61.71 -$16.18 million ($0.75) -8.13

MediWound has higher revenue, but lower earnings than Fortress Biotech. MediWound is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.


Fortress Biotech beats MediWound on 8 of the 12 factors compared between the two stocks.

About Fortress Biotech

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

About MediWound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with's FREE daily email newsletter.